ClinicalTrials.gg
Status unknownNCT05278338Updated Jul 18, 2022

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

A Phase 2 interventional study of JMT103 and Denosumab in Postmenopausal Osteoporosis, sponsored by Shanghai JMT-Bio Inc.. Status unknown at 1 site in China. Open to female participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-07-18.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Osteoporosis, Postmenopausal with a site in China — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · China.

Planned enrollment
9th of 21
200 · median 148
Started
2022
with 2 others
Phase 2
3 of 25
none open now
Registered
21st of 25
by date

Among the 25 studies in Osteoporosis, Postmenopausal with a site in China, this one is the 9th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 2, and was the 21st registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 25 studies in Osteoporosis, Postmenopausal with a site in China is open now. Recruiting first, the newest first:

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Osteoporosis, Postmenopausal with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.

Read the detailed description

This study is a randomized, double-blind, placebo/positive-controlled Phase II clinical study to evaluate the efficacy, safety, immunogenicity and pharmacokinetic characteristics of JMT103 in the treatment of postmenopausal women with osteoporosis. Subjects will be screened within -28 days before treatment, and subjects who meet the inclusion/exclusion criteria will be included in the study. The enrolled postmenopausal women with osteoporosis who meet the diagnostic criteria for osteoporosis will be randomized in a 1:1:1:1:1 ratio into Test Group a (JMT103 45 mg group), Test Group b (JMT103 60 mg group), Test Group c (JMT103 90 mg group), Control Group d (denosumab 60 mg group) and Control Group e (placebo group). JMT103,denosumab and placebo will be administered as a single subcutaneous (SC) injection at the beginning of the treatment phase and at 6 months following the initial dose. Each subject will be followed up for 12 months after the first administration. Throughout the research process, subjects will be required to supplement ≥1000 mg of calcium and ≥800 IU of vitamin D every day.

03

Conditions studied

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women, capable of autonomous action, aged 50-85 years (inclusive);
  2. Menopause is defined as menopause for ≥2 years, which can be spontaneous amenorrhea for ≥2 years or bilateral oophorectomy for ≥2 years. If bilateral oophorectomy status is unknown, the follicle stimulating hormone (FSH) level should be greater than or equal to 40 mIU/mL to confirm the menopausal status;
  3. Meet the diagnostic criteria for osteoporosis: Based on the results of BMD measurement by dual-energy X-ray absorptiometry (DXA), lumbar spine (mean BMD of L1-L4 or more than 2 measurable vertebral bodies), total hip or femur neck BMD is -4.0 ≤ T-value ≤ -2.5; or lumbar spine, total hip or femoral neck BMD is -2.5 \< T-value \< -1.0 and a history of fragility fractures of the proximal humerus, pelvis or distal forearm; or a history of fragility fractures of the hip or vertebral bodies;
  4. The subject can maintain good communication with the investigator and comply with the various requirements of the clinical trial, and is expected to be able to complete the entire trial process;
  5. Be able to be fully informed and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. A history of fractures of more than 2 vertebral bodies;
  2. Subjects with bone metabolic diseases other than osteoporosis: a. various metabolic bone diseases, such as osteomalacia or osteogenesis imperfecta, as these diseases may interfere with the study results; b. Paget's disease; c. Cushing syndrome; d. hyperprolactinemia; e. others;
  3. Currently suffering from hyperparathyroidism or hypoparathyroidism;
  4. Hyperthyroidism or hypothyroidism. Subjects with hypothyroidism on stable (for at least 3 months) thyroid hormone replacement therapy can be selected, but the following conditions must be met: a. If the TSH level is below the normal range, the subject cannot participate in the study. b. If the TSH level is elevated (>5.5 μIU/mL but ≤10.0 μIU/mL), serum T4 should be measured. If the serum T4 is in the normal range, the subject can be selected. If the serum T4 is outside the normal range, the subject cannot participate in the study. c. If the TSH level is greater than 10.0 μIU/mL, the subject cannot participate in the study;
  5. Rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus and other rheumatic immune diseases;
  6. Malabsorption syndrome: Malabsorption syndrome or various gastrointestinal diseases related to malabsorption, such as Crohn's disease and chronic pancreatitis;
  7. Previously or currently suffering from osteomyelitis or osteonecrosis of the jaw; dental surgery or oral surgery wounds that have not healed; acute dental or jaw disease requiring oral surgery; those who have planned to undergo invasive dental surgery during the study period;
  8. Liver disease: a. liver cirrhosis; b. unstable liver disease (defined as ascites, hepatic encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice); c. known or biliary tract abnormalities judged by the investigator (except Gilbert syndrome, asymptomatic gallstones and gallbladder polyps);
  9. Uncontrolled concomitant diseases, including but not limited to: uncontrolled diabetes (>grade 2, 5.0), symptomatic congestive heart failure, hypertension (blood pressure is still ≥150/90 mmHg after standard treatment), unstable angina, sick sinus syndrome (>grade 2, NCI-CTCAE 5.0), severe arrhythmia, history of myocardial infarction within the past 6 months and echocardiogram showing \<50%;
  10. Active bacterial or fungal infection requiring systemic treatment within 7 days before randomization;
  11. Those with active [HBsAg positive with HBV-DNA exceeding 1000 copies/mL (500 IU/mL) or higher than the lower limit of detection, whichever is lower]; subjects with active (HCV antibody positive with HCV-RNA level higher than the upper limit of detection); antibody or syphilis antibody positive;
  12. Those who are known to have active tuberculosis (TB) or suspected of active TB;
  13. Those with malignant tumors within 5 years before screening, except for tumors that are expected to be cured after treatment (such as completely resected basal cell carcinoma or squamous cell carcinoma, cervical cancer or ductal carcinoma of the breast in situ, etc.);
  14. Those who have used intravenous bisphosphonates, fluorides or strontium agents for the treatment of osteoporosis in the last 5 years (from the signing of the form), or oral bisphosphonates for the treatment of osteoporosis (from the date of signing the informed consent form): a. those with cumulative use greater than or equal to 3 years cannot be selected; b. those with cumulative use greater than 3 months but less than 3 years, and the last dose administered within 1 year before the date of signing the informed consent form cannot be selected (those whose last dose was one year or more before the date of signing the informed consent form can be selected); c. those with cumulative use less than or equal to 3 months can be selected;
  15. Those who have used anti-receptor activator of nuclear factor-κB ligand (RANKL) antibody within one year before prior screening;
  16. Those who have received drugs that affect bone metabolism within 3 months before screening: a. parathyroid hormone (PTH) or PTH derivatives, such as teriparatide; b. anabolic hormones or testosterone; c. (equivalent to daily use > 5 mg of prednisone > 10 days); d. sex hormone replacement therapy; e. selective estrogen receptor modulators (SERM), such as raloxifene; f. calcitonin, calcitriol or vitamin D derivatives (cumulative use> 30 days, and used within 6 weeks before the signing of the informed consent form); g. other bone active drugs including anticonvulsants (except benzodiazepines) and heparin; h. long-term systemic use of ketoconazole, adrenocorticotropic hormone (ACTH), cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, or gonadotropin releasing hormone agonists;
  17. Currently receiving other clinical study drugs, and the last dose administered less than 4 weeks or 5 elimination half-lives (t1/2) from the date of study drug administration (whichever is longer);
  18. Those known to have allergies or to JMT103 formulations, control drugs, calcium and vitamin D preparations;
  19. Those who have received the COVID-19 vaccine within 4 weeks before administration;
  20. Those whose blood system, liver and kidney function, and coagulation system examinations meet the following conditions:

    • Blood system (without receiving blood transfusion or hematopoietic stimulating factor treatment within 7 days before the signing of the informed consent form): absolute neutrophil value (ANC) \<1.5×10\^9/L; (PLT) \<75×10\^9/L; (Hb) \<90 g/L;
    • Liver function: total (TBIL)>1.5× (ULN), (ALT)>2.5×ULN (subjects are allowed to be retested after a rest for 2-4 weeks; if the retest shows ALT\<2.5×ULN, they can be included in this study), aspartate aminotransferase (AST)> 2.5×ULN; for subjects with liver or liver cancer: TBIL>3×ULN, ALT>5×ULN, and AST> 5×ULN;
    • Kidney function: urine protein ≥2+ or 24-hour urine protein quantitation ≥1.0 g; * (CrCl) calculated value \<60 mL/min;
    • Coagulation function: : (APTT)>1.5×ULN; international normalized ratio (INR)>1.5×ULN;
  21. Vitamin D deficiency: 25-(OH) vitamin D \<20 ng/mL. Subjects are allowed to receive vitamin D 5000 IU/day for supplementation, and take a retest after 4-6 weeks. If 25-(OH) vitamin D is retested to be >20 ng/mL, the subjects can be enrolled;
  22. Blood calcium abnormalities: current hypocalcemia or hypercalcemia. Serum calcium or serum calcium corrected for albumin is ≤2.2 mmol/L (8.8 mg/dL) or ≥2.9 mmol/L (11.5 mg/dL); subjects are not allowed to use calcium supplements at least 8 hours before blood draw for serum calcium screening determination; Conditions that affect the determination of bone mineral density by dual-energy
  23. Conditions that affect the determination of BMD by dual-energy X-ray absorptiometry: less than 2 measurable lumbar vertebral bodies; height, weight, or waist circumference that may hinder accurate measurement; severe scoliosis and other conditions that affect BMD testing;
  24. Subjects who are judged by the investigator to be at high risk of fractures and must receive active drug treatment;
  25. Subjects who are judged by the investigator to be unsuitable for inclusion in the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Group a

    JMT103 45 mg

    Drug: JMT103

  • Experimental
    Group b

    JMT103 60 mg

    Drug: JMT103

  • Experimental
    Group c

    JMT103 90 mg

    Drug: JMT103

  • Active comparator
    Group d

    Denosumab 60 mg

    Drug: Denosumab

  • Placebo comparator
    Group e

    Placebo

    Drug: Placebo

Interventions

  • DrugNarlumosbartStudies of NarlumosbartNarlumosbart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

  • subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

  • DrugPlacebo

    subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

06

What researchers measure

Primary outcomes

  1. Change rate of lumbar bone mineral density (BMD) from baseline at 12 months of JMT103 treatment

    Dual-energy X-ray absorptiometry (DXA) will be performed to measure the bone mineral density of the subject's lumbar spine (the mean BMD of L1-L4 or more than 2 measurable vertebral bodies), the total hip and the femoral neck during the screening period, and at 3 months, 6 months and 12 months after the first administration and early withdrawal. Bone mineral density will be assessed centrally by DXA.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Change rate of lumbar spine BMD from baseline at 6 months of JMT103 treatment

    Time frame: Baseline and 6 months

  2. Change rate of total hip and femoral neck BMD from baseline at 12 months of JMT103 treatment

    Time frame: Baseline and 12 months

  3. Change rate of serum type I collagen cross-linked C-terminal peptide (s-CTX) from baseline at 1, 3, 6 and 12 months of treatment

    In this study, the central laboratory will be entrusted with the testing of biomarker samples. About 3.5 mL of venous whole blood will be collected each time.

    Time frame: Day 1,15,29 and 3,6,12 months

  4. Change rate of type I procollagen N-terminal propeptide (PINP) from baseline at 1, 3, 6 and 12 months of treatment

    In this study, the central laboratory will be entrusted with the testing of biomarker samples. About 3.5 mL of venous whole blood will be collected each time.

    Time frame: Day 1,15,29 and 3,6,12 months

  5. PK evaluation indicator: JMT103 serum drug concentration

    Venous blood samples will be collected at the specified time points, about 3.5 mL each time, the actual PK blood collection time should be recorded in the eCRF.

    Time frame: Day 2,15,29 and 3,6,12 months

  6. Incidence of JMT103 anti-drug antibodies (ADA) and neutralizing antibodies (NAB)

    Blood samples will be collected at the specified time points, about 3.5 ml each time. The JMT103 anti-drug antibody (ADA) in the serum will be tested by electrochemical immunoassay. ADA-positive serum samples will be tested for neutralizing antibodies (NAB).

    Time frame: Day 1,29 and 3,6,12 months

  7. Types and proportions of adverse events

    An adverse event (AE) can be any unfavorable and unanticipated signs (including abnormal laboratory findings), symptoms, or diseases temporally related to the used (study) drug, regardless of whether it is related to the drug or not. A serious adverse event (SAE) refers to any adverse event that meets one of the following criteria: Leading to death; Life-threatening; Requiring hospitalization or prolongation of hospitalization; Permanent or severe disability or loss of function; Congenital abnormalities or birth defects; Other significant medical events judged by the investigator.

    Time frame: From signing the informed consent form to 6 months after the last administration

07

Study locations

1 of 1 sites recruiting
  • The Second Hospital of Jilin University
    Changchun, Jilin 130041, China
    Recruiting
    • Hanqing Cai, PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Dec 2023, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2022
First posted
Mar 14, 2022
StartActual
Apr 21, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Mar 31, 2024
Last update
Jul 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05278338
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Apr 21, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
Jul 18, 2022

Study contacts

Rong Du
Contact
durong@mail.ecspc.com
0086+010-56081675
Weibo Xia
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Narlumosbart

Start the discussion